Chiara Maria Cattaneo

Junior Group Leader

IRCCS Humanitas Research Hospital
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Year:

2026

Year:

2026

Year:

2026

Drug resistance is a principal limitation to the long-term efficacy of cancer therapies. Cancer genome sequencing can retrospectively delineate the genetic basis of drug resistance, but this requires large numbers of post-treatment samples to nominate causal variants. Here we prospectively identify genetic mechanisms of resistance to ten oncology drugs from CRISPR base editing mutagenesis screens in four cancer cell lines using a guide RNA library predicted to install 32,476 variants in 11 cancer genes. We identify four functional classes of protein variants modulating drug sensitivity and use single-cell transcriptomics to reveal how these variants operate through distinct mechanisms, including eliciting a drug-addicted cell state. We identify variants that can be targeted with alternative inhibitors to overcome resistance and functionally validate an epidermal growth factor receptor (EGFR) variant that sensitizes lung cancer cells to EGFR inhibitors. Our variant-to-function map has implications for patient stratification, therapy combinations and drug scheduling in cancer treatment.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (4)

Koen Hartemink

Prof. dr

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Emanuel Gonçalves

Assistant Professor

Instituto de Engenharia de Sistemas e Computadores Tecnologia e Ciência

PORTUGAL
View details

Jan van Weering

University of Amsterdam

NETHERLANDS
View details

Rene H Medema

Scientific Director

Princess Maxima Center

NETHERLANDS
View details